Key facts
- Bioniq’s last known valuation is $150.0M (Mar 2026).
- It has raised $30.0M; the latest was Merger/Acquisition ($150.0M) in Mar 2026.
- Notable investors include Cristiano Ronaldo, Diogo Dalot, Porsche Ventures, Rocket Internet.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Bioniq
- ·The full record, as it builds
Funding rounds
No funding rounds for Bioniq are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Bioniq
Producer of personalized nutritional supplements intended for optimizing individual health. The company analyzes biochemical data and applies a proprietary algorithm to create tailored micronutrient formulations, utilizing patented granule technology for maximum absorption, enabling individuals to maintain balanced metabolism, improve recovery, enhance cognitive function, and support overall well-being.
- Sector
- Consumer Products and Services (B2C)
- HQ
- London, United Kingdom
- Founded
- 2019
- Employees
- 58
- Website
- bioniq.com/
- Ownership
- Privately Held (backing)
Bioniq doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bioniq shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bioniq in its N-PORT filings yet. We sweep new filings monthly.